CoChat

Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials

Dagenais, Gilles R, Pogue, Janice, Fox, Kim, Simoons, Marteen L, Yusuf, Salim · 2006 · The Lancet

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Abstract

Background Angiotensin-converting-enzyme (ACE) inhibitors reduce cardiovascular mortality and morbidity in patients with heart failure or left ventricular systolic dysfunction (LVSD). Three large trials have assessed the effect of ACE inhibitors in stable patients without these conditions but with atherosclerosis. We undertook a systematic review of the Heart Outcomes Prevention Evaluation (HOPE), the European trial on Reduction Of cardiac events with Perindopril among patients with stable coronary Artery disease (EUROPA), and the Prevention of Events with ACE inhibition (PEACE) studies to determine the consistency with which ACE inhibitors reduce total mortality and fatal and non-fatal cardiovascular events. Methods We computed cardiovascular outcomes and total mortality in the 29,805 patients of these three trials, randomly assigned an ACE inhibitor or placebo and followed up for a mean of about 4.5 years. The results were also analysed within the context of five large trials of ACE inhibitors in patients with heart failure or LVSD. Findings When the findings of the HOPE, EUROPA, and PEACE trials were combined, ACE inhibitors significantly reduced all-cause mortality (7.8 vs 8.9%, p=0.0004), cardiovascular mortality (4.3 vs 5.2%, p=0.0002), non-fatal myocardial infarction (5.3 vs 6.4%, p=0.0001), all stroke (2.2 vs 2.8%, p=0.0004), heart failure (2.1 vs 2.7%, p=0.0007), coronary-artery bypass surgery (6.0 vs 6.9%, p=0.0036) but not percutaneous coronary intervention (7.4 vs…

Overview

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(06)69201-5

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 17 references

Cited by

See all 514

Metadata

Authors
Dagenais, G. R., Pogue, J., Fox, K., Simoons, M. L., & Yusuf, S.
Affiliations
  • Université Laval (CA)
  • Population Health Research Institute (CA)
  • Royal Brompton Hospital (GB)
  • Erasmus MC (NL)
Corresponding author
Dagenais, Gilles R
Venue
The Lancet
Publisher
Elsevier BV
Published
2006-08
Volume
368
Issue
9535
Pages
581-588
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2023755744
Cited by
514
References
17
Citations by year
2026: 3 · 2025: 12 · 2024: 6 · 2023: 9 · 2022: 10 · 2021: 16 · 2020: 16 · 2019: 17 · 2018: 12 · 2017: 20 · 2016: 26 · 2015: 16 · 2014: 29 · 2013: 32 · 2012: 38
FWCI
41.18
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
  • EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
Keywords
ACE inhibitors, atherosclerosis, coronary artery disease, all-cause mortality, cardiovascular mortality, myocardial infarction, stroke, heart failure, perindopril, revascularization, cardiovascular events, HOPE trial, EUROPA trial, PEACE trial, meta-analysis of trials
MeSH terms
Adult, Angiotensin-Converting Enzyme Inhibitors, Coronary Artery Bypass, Blood Pressure, Cardiovascular Diseases, Female, Follow-Up Studies, Humans, Male, Middle Aged, Risk Factors, Randomized Controlled Trials as Topic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. https://app.cochat.ai/papers/10.1016/s0140-6736(06)69201-5
The paper
Dagenais, G. R., Pogue, J., Fox, K., Simoons, M. L., & Yusuf, S. (2006). Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. The Lancet. https://doi.org/10.1016/s0140-6736(06)69201-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.